Tibet Duo Rui Pharmaceutical Co Ltd is a China-based company mainly engaged in the research, development, production and sales of chemical preparations, intermediates and active pharmaceutical ingredients. The Company mainly has self-produced products such as Sodium Acetate Ringer Injection and agent products such as Amoxicillin Sodium and Clavulanate Potassium for Injection. The Company's products mainly include liquid therapy, emergency medication, pediatric medication, psychiatric medication, and analgesic medication. The Company mainly operates its businesses in the domestic market.

Employees

461

Sector

Pharmaceuticals

More about the company

Quotes

Date	Price	Change	Volume
29/26/29	CN¥64.02	+0.28%	6,79,200
28/26/28	CN¥63.84	-3.65%	8,97,600
24/26/24	CN¥66.26	+0.12%	11,14,800
23/26/23	CN¥66.18	-1.61%	9,37,800
22/26/22	CN¥67.26	-1.85%	14,10,300

End-of-day quote Shenzhen S.E.

More quotes

End-of-day quote Shenzhen S.E. 29/09/2026			5-day change	1st Jan Change
64.02 ^CNY	+0.28%		-6.58%	+7.29%

29/09	Certain A Shares of Tibet Duo Rui Pharmaceutical Co.,Ltd. are subject to a Lock-Up Agreement Ending on 29-SEP-2026.	CI
21/09	Tibet Duo Rui Pharmaceutical Co., Ltd.(XSEC:301075) added to S&P Global BMI Index	CI

Market Cap	512.16Cr 76Cr 67Cr 64Cr 58Cr 108.35Cr 7.32TCr 109.42Cr 764.48Cr 294.63Cr 3.74TCr 286.58Cr 280.35Cr 12TCr	P/E 2024	-22.7x	P/E 2025	-46.3x
Enterprise Value	544.83Cr 81Cr 72Cr 68Cr 61Cr 115.26Cr 7.79TCr 116.4Cr 813.25Cr 313.43Cr 3.98TCr 304.86Cr 298.23Cr 13TCr	EV / Sales 2024	6.46x	EV / Sales 2025	32.7x
Free-Float	29.49%	Yield 2024 *	-	Yield 2025	-

29/09	Certain A Shares of Tibet Duo Rui Pharmaceutical Co.,Ltd. are subject to a Lock-Up Agreement Ending on 29-SEP-2026.	CI
21/09	Tibet Duo Rui Pharmaceutical Co., Ltd.(XSEC:301075) added to S&P Global BMI Index	CI
26/08	Tibet Jiakang TImes Technology Development Co., Ltd. agreed to acquire Hubei Duorui Pharmaceutical Co., Ltd. from Tibet Duo Rui Pharmaceutical Co., Ltd. for CNY 77.3 million.	CI
26/08	Tibet Duo Rui Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2026	CI
28/04	Tibet Duo Rui Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
23/04	Tibet Duo Rui Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
23/04	Tibet Jiakang TImes Technology Development Co., Ltd. agreed to acquire Hubei Hairuidi Pharmaceutical Co., Ltd from Tibet Duo Rui Pharmaceutical Co., Ltd. for CNY 2.4 million.	CI
23/04	Tibet Jiakang TImes Technology Development Co., Ltd. entered into an Equity Transfer Agreement to acquire 69% stake in Xiamen Ruitilian Pharmaceutical Technology Co., Ltd. from Tibet Duo Rui Pharmaceutical Co., Ltd. for CNY 27.6 million.	CI
23/04	Tibet Jiakang TImes Technology Development Co., Ltd. agreed to acquire Wuhan Duorui Industrial Co., Ltd from Tibet Duo Rui Pharmaceutical Co., Ltd. for CNY 5.1 million.	CI
27/02	Wang Qingtai and Cao Xiaobing completed the acquisition of an additional 24.30% stake in Tibet Duo Rui Pharmaceutical Co., Ltd. from Tibet Jiakang TImes Technology Development Co., Ltd.	CI
24/02	Trading in Tibet Duo Rui Pharmaceutical's shares to halt	RE
21/01	Wang Qingtai and Cao Xiaobing proposed to acquire additional 24.30% stake in Tibet Duo Rui Pharmaceutical Co., Ltd. from Tibet Jiakang TImes Technology Development Co., Ltd. for approximately CNY 620 million.	CI
05/12	Wang Qingtai, Cui Zihao and Cao Xiaobing completed the acquisition of 29.99% stake in Tibet Duo Rui Pharmaceutical Co., Ltd. from Zhoushan Qingchang Enterprise Management Partnership Enterprise (Limited Partnership) and Tibet Jiakang TImes Technology Development Co., Ltd.	CI

1 day	+0.28%
1 week	-6.58%
Current month	+10.76%
1 month	+15.52%
3 months	+8.12%
6 months	-3.00%
Current year	+7.29%

Tibet Duo Rui Pharmaceutical Co., Ltd. Share Price

Stocks

301075

CNE100004RW5

Pharmaceuticals

Valuation: Tibet Duo Rui Pharmaceutical Co., Ltd.

Chart: Tibet Duo Rui Pharmaceutical Co., Ltd.

Latest news: Tibet Duo Rui Pharmaceutical Co., Ltd.

Quotes and Performance

Price Extremes

Managers and Directors: Tibet Duo Rui Pharmaceutical Co., Ltd.

Other Pharmaceuticals

Financials

Company Profile

Quotes

1 week	63.16	67.87
1 month	54.61	69.74
Current year	44.55	98.29
1 year	40.91	98.29
3 years	12.6	98.29
5 years	12.6	98.29
10 years	12.6	98.29

Manager	Title	Age	Since
Yong Deng CEO	Chief Executive Officer	60	01/12/2018
Chao Li DFI	Director of Finance/CFO	47	01/05/2017
Fen Jin DFI	Director of Finance/CFO	46	01/12/2017

Director	Title	Age	Since
Ying Fei Liu BRD	Director/Board Member	48	21/02/2020
Yong Deng CHM	Chairman	60	01/12/2017
Shao Zhong Zhang BRD	Director/Board Member	70	21/02/2020

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
TIBET DUO RUI PHARMACEUTICAL CO., LTD.	+0.28%	-6.58%	+59.73%	+131.04%	76Cr
ELI LILLY AND COMPANY	-0.01%	+1.24%	+63.06%	+120.55%	1,05600Cr
JOHNSON & JOHNSON	-1.61%	-0.60%	+47.32%	+71.79%	66TCr
ABBVIE INC.	-1.12%	-0.72%	+17.98%	+76.63%	47TCr
ROCHE HOLDING AG	-1.72%	-4.25%	+37.79%	+39.89%	34TCr
NOVARTIS AG	-0.40%	+4.12%	+22.89%	+29.04%	28TCr
ASTRAZENECA PLC	-0.51%	-1.05%	+12.98%	+12.92%	26TCr
AMGEN INC.	+1.32%	+3.27%	+54.63%	+57.63%	23TCr
GILEAD SCIENCES, INC.	-0.61%	-0.91%	+34.33%	+101.87%	19TCr
NOVO NORDISK A/S	-0.24%	-3.21%	-27.79%	-61.37%	17TCr
Average	-0.14%	+0.44%	+32.29%	+58.00%	36.44TCr
Weighted average by Cap.	-0.05%	+1.08%	+39.20%	+70.64%

	2024	2025
Net sales	24Cr 3.59Cr 3.16Cr 2.99Cr 2.72Cr 5.09Cr 344.07Cr 5.14Cr 36Cr 14Cr 175.7Cr 13Cr 13Cr 565.41Cr	15Cr 2.3Cr 2.03Cr 1.92Cr 1.74Cr 3.26Cr 220.46Cr 3.29Cr 23Cr 8.87Cr 112.58Cr 8.63Cr 8.44Cr 362.27Cr
Net income	-6.27Cr -93.38L -82.41L -77.97L -70.71L -1.33Cr -90Cr -1.34Cr -9.35Cr -3.61Cr -46Cr -3.51Cr -3.43Cr -147.25Cr	-10Cr -1.52Cr -1.34Cr -1.27Cr -1.15Cr -2.16Cr -146.09Cr -2.18Cr -15Cr -5.88Cr -75Cr -5.72Cr -5.59Cr -240.07Cr
Net Debt	13Cr 2.01Cr 1.77Cr 1.68Cr 1.52Cr 2.85Cr 192.59Cr 2.88Cr 20Cr 7.75Cr 98Cr 7.54Cr 7.37Cr 316.48Cr	33Cr 4.87Cr 4.3Cr 4.07Cr 3.69Cr 6.91Cr 467.2Cr 6.98Cr 49Cr 19Cr 238.58Cr 18Cr 18Cr 767.75Cr